[{"id":"4a5902b3-41eb-42ff-ac29-03d2cd8d7936","acronym":"","url":"https://clinicaltrials.gov/study/NCT04933422","created_at":"2021-06-21T20:52:49.867Z","updated_at":"2024-07-02T16:35:55.042Z","phase":"Phase 1","brief_title":"CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)","source_id_and_acronym":"NCT04933422","lead_sponsor":"Crimson Biopharm Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • IDH wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CM93"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-02-21"}]